Novartis cuts depression study, nearly erasing $210M Cadent acquisition from pipeline

[cafead]

via Novartis rolled the dice in 2020 with a $210 upfront acquisition of long-time neuroscience partner Cadent Therapeutics. But the bet seems to have come up empty, as the Swiss pharma discontinues a mid-phase major depressive disorder program.

article source